| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6810eeeff7219eca67d91f1fa73decc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6913
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-555 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 |
| filingDate |
2019-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a51f122aa91c00a94038ddb26d10b7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc266726fdc1fd4d22778a311986f99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66333abd298574ec68cc76998ec699dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1ea29f56db4636b52e86a8ece40eba6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1849cf23f409b9c8922b3a9f5f650b5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9979e8928402a684c0667d93a17b2536 |
| publicationDate |
2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020164086-A1 |
| titleOfInvention |
Fusogenic liposomes, compositions, kits and use thereof for treating cancer |
| abstract |
A fusogenic liposome comprising a lipid bilayer comprising a plurality of lipid molecules having 14 to 24 carbon atoms, wherein at least one of said lipid molecules is functionalised with a first functional group of a specific binding pair capable of binding to a complementary second functional group of said binding pair; and optionally further comprising an immune system activating agent functionalised with a complementary second functional group of said binding pair bound to said first functional group is provided. Methods of treatment of cancer using the fusogenic liposome are also provided. |
| priorityDate |
2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |